07:00 , Jul 11, 2016 |  BC Week In Review  |  Financial News

Bone Medical completes private placement

Bone Medical Ltd. (ASX:BNE), West Perth, Australia   Business: Musculoskeletal, Autoimmune   Date completed: 2016-06-27   Type: Private placement   Raised: A$3.5 million ($2.6 million)   Shares: 175 million   Price: A$0.02   Shares after...
07:00 , Aug 22, 2011 |  BioCentury  |  Emerging Company Profile

Tarsa: Fishing in a big pond

While the osteoporosis market is dominated by large companies with established or generic products, Tarsa Therapeutics Inc. believes it can carve out a niche as a second-line therapy for patients with mild to moderate disease....
07:00 , Jun 23, 2008 |  BC Week In Review  |  Company News

Bone Medical, Hyundai Pharmaceutical Co. Ltd. deal

Bone Medical granted Hyundai an exclusive license to commercialize CaPTHymone in South Korea. Bone Medical retains rights elsewhere. Bone Medical will receive an undisclosed upfront payment and is eligible for milestones and royalties. The oral...
07:00 , May 26, 2008 |  BC Week In Review  |  Clinical News

Capsitonin: Phase III start

By year end, Bone Medical will begin a Phase III trial to compare oral Capsitonin given once daily with an intranasal formulation of calcitonin. Bone Medical Ltd. (ASX:BNE), Como, Australia   Product: Capsitonin ( BN002...
07:00 , May 19, 2008 |  BC Week In Review  |  Clinical News

CaPTHymone: Additional Phase I/II data

Additional data from a Phase I/II trial showed that blood levels of PTH fragment increased above baseline shortly after CaPTHymone administration. The company previously said 400 and 800 µg of oral CaPTHymone produced increases in...
08:00 , Feb 11, 2008 |  BC Week In Review  |  Clinical News

CaPTHymone: Phase I/II data

In a Phase I/II trial in 8 healthy post-menopausal women, 400 and 800 µg of oral CaPTHymone produced increases in plasma calcium levels 6 hours after dosing that were comparable to previously reported values for...
08:00 , Feb 4, 2008 |  BC Week In Review  |  Clinical News

Bone Medical preclinical data

In vitro, BN006 produced dose-dependent inhibition of interleukin-6 (IL-6) secretion and down-regulated the secretion of tumor necrosis factor (TNF) by macrophage-type cells. The compound is a TNF regulator. Bone Medical Ltd. (ASX:BNE), Como, Australia  ...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Clinical News

CaPTHymone: Phase I/II started

BNE began a single-blind, crossover, Australian Phase I/II trial in 8 healthy post-menopausal women to compare 400 and 800 µg doses of oral CaPTHymone. Bone Medical Ltd. (ASX:BNE), Como, Australia   Product: CaPTHymone ( BN003...
07:00 , Sep 17, 2007 |  BC Week In Review  |  Company News

Bone Medical board of directors update

Bone Medical Ltd. (ASX:BNE), Como, Australia   Business: Musculoskeletal, Autoimmune   Appointed: Leif Helth Jensen, formerly a director at DentoFit A/S   Resigned: Gabriel Chiappini  ...
07:00 , Aug 27, 2007 |  BC Week In Review  |  Clinical News

Perthoxal: Phase I/IIa start

Next month, BNE will begin a single-blind, crossover, Australian Phase I/IIa trial in 8 healthy post-menopausal women to compare 400 and 800 µg doses of oral Perthoxal. Bone Medical Ltd. (ASX:BNE), Como, Australia   Product:...